Saxenda Offers Weight Loss Hope but Faces Cost and Coverage Hurdles

Saxenda, an injectable weight loss medication, has gained attention as a prescription option for managing obesity. Approved by the FDA for both adults and children, it works by reducing appetite and increasing feelings of fullness. However, its cost and limited insurance coverage remain key considerations for potential users. Saxenda (liraglutide) belongs to the same drug class as Ozempic (semaglutide) but is specifically approved for weight loss. Doctors may prescribe it to adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related condition. It is also authorised for children aged 12 to 17 if their BMI reaches 30 kg/m² and their weight exceeds 60 kg.

The medication is designed to be part of a broader weight loss plan, including a reduced-calorie diet and increased physical activity. Patients can obtain it either in-person through a healthcare provider or online via platforms like Plushcare, Sesame Care, Calibrate, and LifeMD.

In Germany, Saxenda's monthly cost has remained stable at around 285 € for the maintenance dose (e.g., a 5x3 ml pack). Since late 2024, generic versions like Nevolat® have offered a cheaper alternative at 129 € per month. Unlike Ozempic, Saxenda has not seen significant price hikes. However, statutory health insurance does not cover it for obesity treatment—only for diabetes under names like Victoza®. Private insurance may partially cover costs, depending on the policy.

Saxenda is not suitable for everyone. It should not be used by individuals with a rare thyroid cancer called medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2. Additionally, no weight loss injections, including Saxenda, Wegovy®, or Mounjaro®, are covered by German health insurance for obesity alone. Instead, non-medical therapies are recommended. Saxenda provides a medically supervised option for weight management, but its high cost and lack of insurance coverage for obesity treatment pose challenges. Patients must weigh its benefits against out-of-pocket expenses, while exploring alternative therapies if insurance does not apply.